Statements (107)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
gptkb:Company |
| gptkbp:acquisition |
gptkb:Cephalon
gptkb:Actavis_Generics gptkb:Ratiopharm gptkb:Actavis Allergan's generics business focused on strategic acquisitions Actavis (2016) Mylan's generics business |
| gptkbp:categories |
specialty medicines
|
| gptkbp:ceo |
gptkb:Kåre_Schultz
Jeremy Levin (2012-2013) Kåre Schultz (2017-present) Erez Vigodman (2012-2017) Erez Vigodman (2017-2019) |
| gptkbp:clinical_trial |
conducts extensive clinical research
conducts numerous trials globally |
| gptkbp:collaborations |
collaborates with academic institutions
engages in research collaborations with other firms |
| gptkbp:community_engagement |
supports local health initiatives
|
| gptkbp:community_health |
initiates community health programs
participates in global health initiatives. |
| gptkbp:community_support |
supports local communities
|
| gptkbp:conducts_research_on |
gptkb:Dr._Michael_Hayden
|
| gptkbp:conflict |
faced significant debt issues
|
| gptkbp:development |
diverse global workforce
|
| gptkbp:dividend_yield |
pays dividends to shareholders
|
| gptkbp:economic_impact |
expanding in emerging markets
|
| gptkbp:employees |
40,000 (2020)
over 40,000 |
| gptkbp:environmental_impact |
works to reduce environmental impact
|
| gptkbp:financial_performance |
reported strong financial performance in recent years
|
| gptkbp:founded |
1901
|
| gptkbp:founder |
gptkb:Eli_Hurvitz
|
| gptkbp:global_presence |
over 60 countries
|
| gptkbp:has_diversity_initiatives |
expanding into biosimilars
|
| gptkbp:head_of_state |
gptkb:Dr._Richard_D._Smith
|
| gptkbp:headquarters |
gptkb:Africa
gptkb:Europe gptkb:Asia gptkb:Latin_America gptkb:North_America Petah Tikva, Israel |
| https://www.w3.org/2000/01/rdf-schema#label |
TEVA
|
| gptkbp:industry |
gptkb:pharmaceuticals
Pharmaceuticals |
| gptkbp:innovation |
focuses on innovative drug development
|
| gptkbp:instruction_set |
diverse product pipeline
|
| gptkbp:invention |
holds thousands of patents
|
| gptkbp:investment |
invests in innovative technologies
|
| gptkbp:investment_strategy |
volatile stock performance
|
| gptkbp:leadership |
leader in generic pharmaceuticals
|
| gptkbp:legal_issue |
involved in various lawsuits
|
| gptkbp:market_cap |
$12.5 billion (2021)
$10.5 billion (2021) |
| gptkbp:market_share |
one of the largest in the world
|
| gptkbp:marketing_strategy |
emphasis on cost-effective solutions
|
| gptkbp:mission |
to improve health and enhance the quality of life
|
| gptkbp:partnership |
gptkb:Mylan
gptkb:Boehringer_Ingelheim gptkb:Pfizer collaborates on global health initiatives |
| gptkbp:partnerships |
various biotech companies
|
| gptkbp:product |
gptkb:Pro_Air_HFA
gptkb:Ajovy gptkb:Copaxone Teva's biosimilars Teva's cardiovascular products Teva's central nervous system products Teva's dermatology products Teva's gastrointestinal products Teva's generic drugs Teva's infectious disease products Teva's injectable products Teva's metabolic disease products Teva's oncology products Teva's ophthalmic products Teva's over-the-counter products Teva's pain management products Teva's respiratory products Teva's specialty medicines Teva's urology products Teva's vaccines Teva's women's health products |
| gptkbp:products |
generic drugs
|
| gptkbp:recalls |
has experienced several product recalls
|
| gptkbp:regulatory_compliance |
adheres to strict regulatory standards
|
| gptkbp:research_and_development |
focus on complex generics
|
| gptkbp:revenue |
$16.7 billion (2020)
|
| gptkbp:safety |
prioritizes product safety and efficacy
|
| gptkbp:social_responsibility |
committed to ethical practices
|
| gptkbp:stock_exchange |
gptkb:NYSE
|
| gptkbp:stock_symbol |
gptkb:TEVA
|
| gptkbp:strategic_goals |
aims for sustainable growth
|
| gptkbp:subsidiaries |
gptkb:Teva_Pharmaceuticals_USA
|
| gptkbp:subsidiary |
gptkb:Teva_Pharmaceuticals_USA
gptkb:Teva_Canada_Limited gptkb:Teva_UK_Limited |
| gptkbp:supply_chain |
global supply chain management
|
| gptkbp:sustainability_initiatives |
environmental responsibility programs
|
| gptkbp:traded_on |
gptkb:NYSE
|
| gptkbp:training |
provides extensive training programs
|
| gptkbp:website |
www.tevapharm.com
|
| gptkbp:bfsParent |
gptkb:Teva
gptkb:pharmaceuticals |
| gptkbp:bfsLayer |
4
|